MNK

马林克罗制药
NYSE

实时行情|Nasdaq Last Sale

2.870
-0.230
-7.42%
交易中 12:39 07/16 EDT
开盘
3.140
昨收
3.100
最高
3.197
最低
2.780
成交量
476.89万
成交额
--
52周最高
8.73
52周最低
1.000
市值
2.42亿
市盈率(TTM)
-0.1982
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测MNK价格均价为2.778,最高价位4.000,最低价为1.000。

EPS

MNK 新闻

更多
Mallinckrodt opts in for two new RNAi assets from Silence Therapeutics
Silence Therapeutics announces that collaboration partner Mallinckrodt (NYSE:MNK) has exercised its option for exclusive global licenses for two additional
seekingalpha · 13分钟前
FDA Advisory Committee Recommends Mallinckrodt's Trelipressin
The Cardiovascular and Renal Drugs Advisory Committee of the FDA votes in favor of Mallinckrodt's (MNK) investigational agent, terlipressin, to treat adults with hepatorenal syndrome type 1.
Zacks · 2小时前
The Daily Biotech Pulse: Mallinckrodt Gets FDA Panel Backing, Regulatory Setback For Tricida, Relay Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)
Benzinga · 4小时前
FDA Ad Com backs Mallinckrodt's terlipressin in close vote
The FDA's Cardiovascular and Renal Drugs Advisory Committee voted 8-7 that the benefits of Mallinckrodt's (MNK +11.1%) terlipressin outweigh the risks for
seekingalpha · 15小时前
Mallinckrodt Announces U.S. Food and Drug Administration (FDA) Advisory Committee Voted to Recommend Terlipressin for Approval to Treat Patients with Hepatorenal Syndrome Type 1 (HRS-1)
Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted to recommend approval for its investigational agent terlipressin t
PR Newswire · 18小时前
Benzinga Pro's Top 5 Stocks To Watch For Wed., Jul. 15, 2020: BKNG, PLNT, ABT, XRF, MNK
Today's 5 Stock Ideas:  Booking.com (BKNG) - A sympathy play. When positive news of Moderna's (MRNA) COVID-19 vaccine hit the market Tuesday afternoon, the first group of stocks to react
Benzinga · 1天前
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14)
Benzinga · 1天前
Mallinckrodt up 12% on prospects for Ad Com thumbs up on terlipressin
The FDA's Cardiovascular and Renal Drugs Advisory Committee will meet virtually on Wednesday, July 15, to review and discuss Mallinckrodt's (MNK +12.1%) ma
seekingalpha · 2天前

所属板块

制药
-0.91%
制药与医学研究
-0.91%

热门股票

代码
价格
涨跌幅

MNK 简况

Mallinckrodt public limited company负责开发、制造、营销和分销品牌和通用名特种药品与疗法。该公司从事多领域治疗,如自身免疫与罕见疾病专业领域(包括神经病学、风湿病学、肾脏学、眼科学和肺脏学)、免疫治疗与新生儿重症监护呼吸治疗、镇痛剂与止血产品和中枢神经系统药物。该公司的业务部门包括特种品牌药品和特种通用名药品。特种品牌药品部门负责生产和销售品牌药品与疗法。特种通用药品部门负责生产和销售由生物制剂、药用鸦片类、合成受控物质、对乙酰氨基酚和其他活性成分组成的特种通用名药品和活性药物成分(API)。该公司产品包括Acthar、Inomax、Ofirmev、Therakos免疫治疗、Hemostasis产品和StrataGraft。
展开

微牛提供Mallinckrodt PLC(NYSE-MNK)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的MNK股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易MNK股票基本功能。